Page last updated: 2024-10-25

clinofibrate and Hyperlipoproteinemia Type II

clinofibrate has been researched along with Hyperlipoproteinemia Type II in 1 studies

Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).

Research Excerpts

ExcerptRelevanceReference
"Clinofibrate was given to 15 patients with hyperlipidemia, for 6-8 weeks at the daily dose of 600 mg, and its effect on 3 biliary lipid components (cholesterol, bile acids and phospholipids) and on the lithogenic index was investigated."1.26Effect of clinofibrate, a new hypolipidemic agent, on biliary and serum lipids in patients with hyperlipidemia. ( Asano, T; Fujiyama, M; Ishikawa, K; Kajiyama, G; Kukita, H; Miki, H; Mishima, T; Murata, K; Takeuchi, N, 1982)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Takeuchi, N1
Kukita, H1
Kajiyama, G1
Fujiyama, M1
Ishikawa, K1
Miki, H1
Mishima, T1
Murata, K1
Asano, T1

Other Studies

1 other study available for clinofibrate and Hyperlipoproteinemia Type II

ArticleYear
Effect of clinofibrate, a new hypolipidemic agent, on biliary and serum lipids in patients with hyperlipidemia.
    Atherosclerosis, 1982, Volume: 42, Issue:2-3

    Topics: Adult; Aged; Bile; Bile Acids and Salts; Cholesterol; Female; Glycolates; Humans; Hyperlipidemias; H

1982